公募基金四季报风云：基金经理激战AI泡沫论，半数基金年底减仓

Core Viewpoint - The 2025 Q4 public fund reports reveal a complex landscape characterized by "the strong getting stronger and the obscure emerging" [3] Group 1: Fund Performance - Over 40% of active equity products achieved positive quarterly returns, yet the overall fund profits still incurred losses exceeding 10 billion [4] - The top-performing fund, Yongying High-end Equipment Select A, reported a quarterly return of 56.42%, while some healthcare-themed funds experienced losses exceeding 23% [4] - Mini funds like Zhongou Cycle Select saw their scale surge from 0.36 billion to 15.75 billion, marking an increase of over 42 times [4] Group 2: Fund Manager Strategies - More than half of active equity funds opted to reduce stock positions, with over 10 products decreasing their positions by more than 20% [5] - The champion fund Yongying Technology Select A reduced its stock position from 94.41% to 80.34%, a decrease of over 14 percentage points [5] - Fund managers are showing caution towards AI hardware valuations, seeking relatively undervalued segments within the industry [9] Group 3: AI Bubble Debate - The debate over whether the AI sector has entered a bubble has intensified, with differing views among fund managers [10] - Some managers believe the AI industry is in the early stages of bubble formation, while others argue that valuations have returned to reasonable levels [11] - The core of the bubble debate revolves around the timing of technological advancements and the pace of commercial application [12] Group 4: Investment Opportunities - Fund managers are shifting their focus from beta to alpha, emphasizing the importance of stock selection [17] - In the innovative drug sector, opportunities are identified in the overseas expansion of the industry chain and domestic substitution of equipment [18] - The overall return levels in the equity market may decline, but significant structural excess return opportunities still exist [18]